Next Article in Journal
Adequate Management of Postoperative Complications after Esophagectomy: A Cornerstone for a Positive Outcome
Previous Article in Journal
Advances in Understanding of Metabolism of B-Cell Lymphoma: Implications for Therapy
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Cancers
Volume 14
Issue 22
10.3390/cancers14225555
cancers-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles thumb_up
...
Endorse textsms
...
Comment
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Article

Modified BEST-J Score Model Predicts Bleeding after Endoscopic Submucosal Dissection with Fewer Factors

by
Tomoyuki Okada
1,*,
Tsuyoshi Mikamo
1,
Wataru Hamamoto
1,
Taku Iwamoto
1,
Toshiaki Okamoto
1,
Kazunori Maeda
1,
Atsushi Yanagitani
1,
Kiwamu Tanaka
1,
Hajime Isomoto
2 and
Naoyuki Yamaguchi
3
1
Tottori Prefectural Central Hospital, Tottori 680-0901, Japan
2
Division of Medicine and Clinical Science, Faculty of Medicine, Tottori University, Yonago 683-8504, Japan
3
Department of Endoscopy, Nagasaki University Hospital, Nagasaki 852-8501, Japan
*
Author to whom correspondence should be addressed.
Cancers 2022, 14(22), 5555; https://doi.org/10.3390/cancers14225555
Submission received: 6 October 2022 / Revised: 1 November 2022 / Accepted: 10 November 2022 / Published: 12 November 2022
Browse Figures
Versions Notes

Abstract

:

Simple Summary

BEST-J score is a model for predicting bleeding after gastric endoscopic submucosal dissection (ESD); however, it is complicated. Several post-ESD bleeding prediction models exist but have not been externally validated. Moreover, there are no post-ESD bleeding prediction models that incorporate nutritional indicators. This study aimed to predict post-ESD bleeding more simply by incorporating nutritional indicators and verify generalizability using an external cohort. This study could more quickly predict post-ESD bleeding.

Abstract

This study constructed a simplified post-endoscopic submucosal dissection (ESD) prediction model with a prognostic nutritional index (PNI). A total of 449 patients who underwent gastric ESD was included, divided with a ratio of 2:1, and assigned to the model or validation cohort. A prediction model of post-ESD (modified BEST-J score) was constructed using the model cohort. The modified BEST-J score was evaluated by comparing its accuracy to the BEST-J score in the validation cohort. Within 4 weeks of ESD, melena, hematemesis, or a 2 g/dL or greater decrease in hemoglobin level that required esophagogastroduodenoscopy was defined as post-ESD bleeding. In the model cohort, 299 patients were enrolled and 25 (8.4%) had post-ESD bleeding. Independent risk factors for post-ESD bleeding were use of P2Y12RA, tumor size > 30 mm, location of lesion at lower one-third of the stomach, and PNI ≤ 47.9. Constructing the modified BEST-J score based on these variables, the sensitivity, specificity, and positive likelihood ratio were 73.9%, 78.1%, and 3.37. When comparing the modified BEST-J score to the BEST-J score in the validation cohort, no significant difference was observed by ROC-AUC (0.77 vs. 0.75, p = 0.81). Modified BEST-J score can predict post-ESD bleeding more simply, with the same accuracy as the BEST-J score.

1. Introduction

Gastric endoscopic submucosal dissection (ESD) is a useful and minimally invasive treatment. ESD has a similar 5-year overall survival, disease-specific survival, and a lower risk of complications from surgery [1,2]. Moreover, ESD is minimally invasive and conserves the stomach, improving quality of life [2]. ESD-related complications include perforation and delayed bleeding, which can have severe outcomes, requiring blood transfusions and emergency endoscopic hemostasis [3,4]. Several studies report that age, comorbidity, use of antithrombotics or anticoagulants, time taken for ESD, tumor location, and tumor size are related to delayed bleeding [3,4,5,6]. Hatta et al. reported a model that predicts post-ESD bleeding: BEST-J score [7]. The BEST-J score was constructed based on a large-scale multicenter study in Japan and demonstrated good discrimination and calibration [7]. However, the BEST-J score required a combination of many variables, which was complicated. Regarding postoperative complications, preoperative nutritional states affect postoperative outcomes and some nutritional indicators have been reported [8,9,10,11,12]. The prognostic nutritional index (PNI) is a nutritional indicator calculated by total lymphocyte count and serum albumin level, suggested by Onodera et al. [13]. Several studies have shown that preoperative PNI states for gastrointestinal cancer are useful predictors of postoperative complications [14,15,16]. To our knowledge, a few models that predict post-ESD bleeding exist [7,17]. Moreover, there is no predictive model of post-ESD bleeding, considering PNI, including the BEST-J score. Hence, this study sought to develop a simplified post-ESD prediction model that incorporates the PNI based on the BEST-J score.

2. Materials and Methods

2.1. Study Design

This single-center retrospective observational study was approved by the Institutional Review Board of Prefectural Central Hospital (Tottori, Japan; approval number: 2020-86) and performed according to the Declaration of Helsinki [18]. Informed consent was obtained from the hospital website by the opt-out method.
Three steps were performed in this study. First, using the model cohort, components in the post-ESD bleeding model were identified using the BEST-J score and PNI. Regarding validity, the constructed predictive model was checked in the model cohort. Finally, using another validation cohort, we evaluated the validity of the predictive model by comparing it to the BEST-J score. Cases undergoing gastric ESD from January 2011 to December 2021 were randomly divided in a 2:1 ratio and assigned to either the model or validation cohort (Figure 1).
Cases were assigned to prevent overlap between the two cohorts and cases undergoing multiple ESDs were assigned to one cohort. All data were collected from an inclusive, computerized hospital database.

2.2. Patients

Patients treated with gastric ESD at the Tottori Prefectural Central Hospital (Tottori, Japan) from January 2011 to December 2021 participated in this study. Patients who discontinued treatment in the middle of ESD were excluded. Patients treated with laparoscopic and endoscopic cooperative surgery and those who refused to participate in this study were also excluded.

2.3. ESD Procedure

ESD was performed on lesions diagnosed or strongly suspected of early gastric cancer according to the guidelines for ESD produced by the Japan Gastroenterological Endoscopy Society (JGES) [19]. Based on previous reports [20,21,22,23], ESD was performed in a consistent procedure. First, the scope of the resected lesion was marked with a high-frequency generator (ERBR, Elektromed-VIO300D; Tubingen, Germany). Then, a mixture of glycerin solution, sodium hyaluronate, and indigo carmine was injected into the submucosa to lift the lesion. After swelling of the submucosa, the submucosal layer of the lesion was dissected with a diathermy knife (FlushKnife N-S, DK2620JI; Fujifilm, Tokyo, Japan or dual knife, KD-655L; Olympus, Tokyo, Japan) or an insulation-tipped diathermy knife (IT-Knife 2, KD611L; Olympus, Tokyo, Japan). Finally, the lesion was resected en bloc. ESD was performed using GIF-260J (Olympus, Tokyo, Japan) or GIF-H290 (Olympus, Tokyo, Japan), with the tip attached to a hood (D-201-11804; Olympus, Tokyo, Japan or Elastic Touch, F-30; Top, Tokyo, Japan). Endoscopic closure of ESD-treated site was not performed in all cases. After the first day of ESD, all patients were intravenously administered proton pump inhibitors or potassium-competitive acid blockers. Second-look esophagogastroduodenoscopy (EGD) was performed if the doctor who performed ESD deemed it necessary. In cases requiring a second-look EGD, if bleeding blood vessels or stumps of exposed blood vessels were visually recognized, patients were treated with coagulation and hemostasis. Patients who underwent antithrombotic treatment were managed as per JGES guidelines [24,25,26].

2.4. Predictive Variables

Referring to the BEST-J score, PNI, previous reports, and clinical experience, the twenty-one predictors selected were: age, sex, body mass index (BMI), Charlson Comorbidity Index [27], treatment with artificial dialysis [7], use of low-dose aspirin [6,7], use of P2Y12 receptor antagonist (P2Y12RA) [7], use of phosphodiesterase 3 inhibitor (PDE3 inhibitor) [7], use of warfarin [6,7], use of direct oral anticoagulant (DOAC) [7], tumor size > 30 mm [4,7], location of a lesion at lower one-third of the stomach [3,7], presence of multiple tumors [7], undifferentiated cancer [7], tumor pathologically diagnosed as beyond SM1 invasion [7], ESD duration > 120 min [3], failure of en bloc resection, the presence of gastric mucosal atrophy [7], C-reactive protein (CRP) changes before and after ESD, white blood cell (WBC) changes before and after ESD, and PNI [13]. Regarding antithrombotic agents, withdrawal, continuation, and replacement with heparin or low-dose aspirin were considered variables. Mucosal atrophy was evaluated based on the classification of Kimura and Takemoto [28]. PNI was calculated as follows [13]:
PNI = 10 × Alb [g/dL] + 0.005 × total lymphocyte count

2.5. Outcome Criteria

Post-ESD bleeding was the primary observational goal of the study. Based on previous reports [7,29,30], post-ESD bleeding was defined as EGD performance based on findings suggestive of bleeding within 4 weeks of ESD. Findings suggestive of bleeding included the appearance of melena or hematemesis, with a decrease in the hemoglobin level by >2 g/dL. Preventive hemostasis during second-look EGD was not considered for post-ESD bleeding.

2.6. Statistical Analysis

In the model cohort, univariate analysis was performed using Fisher’s exact test or the Mann–Whitney U test. Variables with a p-value < 0.05 were eligible for multivariate analysis. The multivariate model incorporated these variables and was evaluated using the backward elimination method by multivariable logistic regression. Variables with a p-value < 0.05 were elements of the final model. To avoid multicollinearity, a variance inflation factor (VIF) was used. Variables with VIF > 10 were ruled out. The Hosmer–Lemeshow test was used to measure the fitness of the model. We assigned each variable a score based on the multivariate analysis’s β regression coefficient. The area under the receiver operating characteristic curve (ROC-AUC) was used as a measure of discrimination. To investigate the possibility of overfitting the model, 5-fold cross-validation was executed. The ROC-AUC between the naive prediction model and the validated model was compared for cross-validation. Next, based on the created model, we classified cases in the validation cohort into three groups: low risk, intermediate risk and high risk. We evaluated trends in bleeding rates among them using Cochran–Armitage test. Then, we compared the performance between the created model (now called “modified BEST-J score”) and the BEST-J score by ROC-AUC using DeLong test. All statistical analyses were executed with EZR software [31].

3. Results

3.1. Patients in the Model Cohort

In total, 449 patients treated with gastric ESD from January 2011 to December 2021 were enrolled. We divided them into groups with a 2:1 ratio. We assigned 299 patients to the model cohort and 150 to the validation cohort. The clinical characteristics and background of patients in the model cohort are presented in Table 1. The mean ± standard deviation (SD) age was 73 ± 9.04 years and 94 patients were female. The mean ± SD PNI was 49.6 ± 5.19.

3.2. Post-ESD Bleeding in the Model Cohort

Of the 299 patients in the model cohort, 25 experienced post-ESD bleeding. To detect predictive factors, the post-ESD bleeding and control groups were contrasted (Table 2). The factors include undergoing dialysis (p = 0.0020), taking P2Y12RA (p < 0.001), tumor size > 30 mm (p = 0.0043), lesion location in the lower one-third of the stomach (p = 0.0044), and PNI (mean ± SD of post-ESD bleeding vs. control, 46.2 ± 4.79 vs. 50 ± 5.12, p < 0.001). Using ROC analysis, the cutoff value of PNI was defined as 47.9.
According to the multivariable logistic regression analysis, P2Y12RA (odds ratio (OR), 10.5; β regression coefficient (β), 2.35; 95% confidence interval (CI), 2.73–40.3; p < 0.001), tumor size > 30 mm (OR, 6.79; β, 1.91; 95% CI, 2.07–22.2; p = 0.0016), a lesion in the lower one-third of the stomach (OR, 3.49; β, 1.25; 95% CI, 1.24–9.83; p = 0.018), and PNI ≤ 47.9 (OR, 7.48; β, 2.01; 95% CI, 2.34–23.4; p < 0.001) (Table 3) had VIF < 10. Undergoing dialysis had no significant difference. The Hosmer–Lemeshow test showed a good fit for the model (p > 0.05).
Based on the β regression coefficient of multivariable logistic regression, we assigned two points to P2Y12RA, tumor size > 30 mm, and PNI ≤ 47.9 and one point to a lesion located in the lower one-third of the stomach (defined as the modified BEST-J score). Among the patients who had scores of 0, 1, 2, 3, 4, 5, and 7, the proportion of post-ESD bleeding was 0%, 3.23%, 7.02%, 16.7%, 36.4%, 42.3%, and 100%, respectively. Calculated by Spearman’s rank correlation test, the total score was positively correlated with the rate of post-ESD bleeding (rs = 0.33, p < 0.001, Figure 2).
The ROC analysis showed that the sensitivity, specificity, and positive likelihood ratio were 73.9%, 78.1%, and 3.37, respectively. A five-fold cross-validation was performed and ROC-AUC was 0.82 (range, 0.61–0.96) for naïve prediction and 0.71 (range, 0.51–0.90) after cross-validation.

3.3. Comparison between the Modified BEST-J and BEST-J Scores in the Validation Cohort

The clinical characteristics and background of patients in the validation cohort are presented in Table 1. Of the 150 patients in the validation cohort, 13 experienced post-ESD bleeding. Each patient was scored based on the BEST-J and modified BEST-J scores. The proportion of post-ESD bleeding in patients who scored 0, 1, 2, 3, 4, 5, 6, 7, 8, and 9 according to the BEST-J score was 1.86%, 6.52%, 7.14%, 23.1%, 33.3%, 0%, 0%, 0%, 100%, and 0%, respectively, whereas in patients who scored 0, 1, 2, 3, 4, and 5 according to the modified BEST-J score was 2%, 5.56%, 18.2%, 23.5%, 33.3%, and 25%, respectively (Figure 3).
A positive correlation between post-ESD bleeding rate and the total score was observed in the BEST-J and modified BEST-J scores (rs = 0.25 vs. 0.29, p = 0.002 vs. p < 0.001); the Hosmer–Lemeshow test showed a good model fit (both p > 0.05). Based on modified BEST-J scores, classifying cases with a score of 0,1 as low risk, those with a score of 2 as intermediate risk, those with a scores of 3 or more as high risk, post-ESD bleeding rate tended to increase from low to high risk (p < 0.001). Similar trends were observed among low, intermediate, high, and very high groups classified by BEST-J scores (p < 0.01). ROC analysis revealed that the sensitivity, specificity, and positive likelihood ratio were 61.5%, 80.1%, 3.09, and 0.747, respectively, for the BEST-J score and 69.7%, 76.9%, 3.02, and 0.767, respectively, for the modified BEST-J score. ROC-AUC was superior to those using the modified BEST-J score; however, no significant difference was observed (0.77 vs. 0.75, p = 0.81, Figure 4).

4. Discussion

This study showed that the modified BEST-J score could predict post-ESD bleeding based on four variables: the use of P2Y12RA, tumor size > 30 mm, location of a lesion at the lower one-third of the stomach, and PNI ≤ 47.9; the modified BEST-J score performed as well as the BEST-J score in the validation cohort. Post-ESD bleeding is a major complication of ESD. Reportedly, 1.3–11.9% of patients who undergo ESD experience post-ESD bleeding [32], which can occur after the patient is discharged [32], making rapid treatment difficult; hence, predicting post-ESD bleeding is necessary. This study constructed a predictive model for post-ESD bleeding with four variables, including PNI. We showed that it was as accurate as the BEST-J score using a validation cohort. Choe et al. developed a prediction model with three variables: continued use of antithrombotic agents, specimen size ≥ 49 mm, and age < 62 years [17]; however, internal validity was not evaluated. The BEST-J score showed good discrimination (c-statistic was 0.70) and good calibration in the external validation cohort [7]. This model is useful in predicting post-ESD bleeding; however, it should consider 10 factors. The modified BEST-J score can predict post-ESD bleeding with fewer variables; hence, it can predict bleeding more quickly.
This study showed that only P2Y12RA intake was related to post-ESD bleeding and not the discontinuation of antithrombotic agents. Hakoda et al. reported that P2Y12RA had the highest bleeding risk among antiplatelet agents and continued or discontinued aspirin or PDE3 inhibitor administration did not affect post-ESD bleeding [33]. It has been reported that endoscopic treatment with continued aspirin does not increase the risk of postoperative bleeding [34,35]. PDE3 inhibitors, such as cilostazol, inhibit platelet aggregation without prolonging bleeding time in vivo [36] and do not cause an increased risk of serious bleeding events [37]. Anticoagulants are reported as a risk factor for post-ESD bleeding [6,7]. On the other hand, appropriate adjustment of PT-INR can reduce bleeding risk and anticoagulants are not a bleeding risk when adjusted appropriately for patient background [38,39]. Moreover, several studies show a relationship between gastroprotective agents and anticoagulants. Concomitant use of gastroprotective agents and anticoagulants reduces the risk of gastrointestinal bleeding [40,41]. In this study, all patients who underwent ESD were administered proton pump inhibitors or potassium-competitive acid blockers; hence, these agents may have reduced the risk of post-ESD bleeding caused by anticoagulants. Adenosine-5′-diphosphate promotes wound healing by activating the P2Y12 receptor [42]; hence, P2Y12RA may inhibit wound healing rather than platelet aggregation, which promotes post-ESD bleeding.
Several reports have indicated that preoperative malnutrition is associated with postoperative complications [14,43]. Lee et al. reported that malnourished patients had more wound complications [43]. Among patients 85 years and older who underwent gastric ESD, those with a lower PNI had a poorer survival rate [44]. However, this study is the first to report the association between PNI and ESD complications, including post-ESD bleeding. According to the BEST-J score, chronic renal failure requiring dialysis is considered a high-risk factor for post-ESD bleeding [7]. Severe chronic renal failure with decreased glomerular filtration rate was more common in patients with low PNI [45]; hence, PNI may have also been involved in the BEST-J score. Albumin and lymphocytes contribute to wound healing [46,47], and a low PNI, which reflects these conditions, may have resulted in delayed recovery and bleeding. Preoperative nutritional therapy reduces postoperative complications [48]; hence, nutritional therapy before ESD can reduce postoperative bleeding in patients with a low PNI.
There is an association between tumor size and postoperative bleeding [4,7,17]. Although the definition of tumor size varies among reports, it is defined as at least 30 mm. Hence, this study defined tumor size as ≥ 30 mm. Tumor location is associated with postoperative bleeding; however, studies differ in whether the risk factor is in the upper or lower stomach [4,7]. Chung et al. reported that lesions located in the upper part of the stomach were a risk factor for post-ESD bleeding [4]. However, Hatta et al. reported lesions located in the lower third part of the stomach were a risk factor [7]. This study showed that lesions in the lower part of the stomach were risk factors for post-ESD bleeding. The lower stomach can be exposed to alkaline reflux from the duodenum, causing local gastric acid hypersecretion and resulting damage; therefore, it may be a risk factor for post-ESD bleeding [49].
Including a multicenter study, several studies have been conducted on the timing of bleeding. Nam et al. reported that age, resection size, procedure time, location of lesion in the stomach, erosion, and clopidogrel affected the occurrence of early post-ESD bleeding [50]. In a multicenter study, taking anticoagulants, undergoing dialysis, taking antiplatelet agents, tumor size, multiple tumor, and location of the lesion in the stomach were reported as a risk factor for early post-ESD bleeding [51]. This study showed the use of P2Y12RA, tumor size > 30 mm, and location of a lesion at the lower one-third of the stomach were risk factors for post-ESD bleeding; however, it did not examine whether bleeding occurred early after ESD. Since different risk factors for early post-ESD bleeding were reported by each study, a prospective study with and without risk factors needs to be conducted.
Several limitations are included in this study. First, this was a single-institution retrospective study; therefore, it had a smaller sample size and was more susceptible to selection bias than a multicenter study. In addition, since this study was validated in an internal cohort, it could be subject to selection bias. Moreover, logistic regression analysis requires 10 outcomes for one independent variable; however, the number of post-ESD bleeding events was insufficient for the number of independent variables in the model cohort. There may be a risk of overfitting; therefore, cross-validation and validation with alternative internal cohorts were used to ensure that the modified BEST-J score had sufficient accuracy. Finally, there is a difference in the proportion of cases with variables between model cohort and validation cohort, which may affect the results.

5. Conclusions

This study showed that the modified BEST-J score could predict post-ESD bleeding with fewer variables than the BEST-J score. Post-ESD bleeding can be predicted quickly using the modified BEST-J score.

Author Contributions

Data acquisition, analysis, interpretation, and original draft preparation, T.O. (Tomoyuki Okada); ESD performance and ESD-related data acquisition, T.M., W.H., T.I., T.O. (Toshiaki Okamoto), K.M., A.Y. and K.T.; Conceptualization and design, A.Y. and N.Y.; Conceptualization, design, and original draft preparation, H.I. and N.Y. All authors have read and agreed to the published version of the manuscript.

Funding

This research received no external funding.

Institutional Review Board Statement

The study was conducted in accordance with the Declaration of Helsinki and approved by the Institutional Review Board of Prefectural Central Hospital (Tottori, Japan; approval number: 2020-86).

Informed Consent Statement

Informed consent was obtained from all subjects involved in the study by opt-out method on the hospital website.

Data Availability Statement

All data generated or analyzed during the present study are included in this article.

Conflicts of Interest

The authors declare no conflict of interest.

Abbreviations

ESD: endoscopic submucosal dissection; PNI, prognostic nutritional index; JGES, Japan Gastroenterological Endoscopy Society; BMI, body mass index; P2Y12RA, P2Y12 receptor antagonist; PDE3, phosphodiesterase 3; DOAC, direct oral anticoagulant; SM, submucosal layer; CRP, C-reactive protein; WBC, white blood cell; VIF, variance inflation factor; ROC-AUC, area under the receiver operating characteristic curve; SD, standard deviation; PT-INR, prothrombin time-international normalized ratio.

References

  1. Abdelfatah, M.M.; Barakat, M.; Ahmad, D.; Ibrahim, M.; Ahmed, Y.; Kurdi, Y.; Grimm, I.S.; Othman, M.O. Long-term outcomes of endoscopic submucosal dissection versus surgery in early gastric cancer: A systematic review and meta-analysis. Eur. J. Gastroenterol. Hepatol. 2019, 31, 418–424. [Google Scholar] [CrossRef] [PubMed]
  2. Liu, Q.; Ding, L.; Qiu, X.; Meng, F. Updated evaluation of endoscopic submucosal dissection versus surgery for early gastric cancer: A systematic review and meta-analysis. Int. J. Surg. 2020, 73, 28–41. [Google Scholar] [CrossRef]
  3. Toyokawa, T.; Inaba, T.; Omote, S.; Okamoto, A.; Miyasaka, R.; Watanabe, K.; Izumikawa, K.; Horii, J.; Fujita, I.; Ishikawa, S.; et al. Risk factors for perforation and delayed bleeding associated with endoscopic submucosal dissection for early gastric neoplasms: Analysis of 1123 lesions. J. Gastroenterol. Hepatol. 2012, 27, 907–912. [Google Scholar] [CrossRef] [PubMed]
  4. Chung, I.K.; Lee, J.H.; Lee, S.H.; Kim, S.J.; Cho, J.Y.; Cho, W.Y.; Hwangbo, Y.; Keum, B.R.; Park, J.J.; Chun, H.J.; et al. Therapeutic outcomes in 1000 cases of endoscopic submucosal dissection for early gastric neoplasms: Korean ESD study group multicenter study. Gastrointest. Endosc. 2009, 69, 1228–1235. [Google Scholar] [CrossRef] [PubMed]
  5. Xu, S.; Chai, N.; Tang, X.; Linghu, E.; Wang, S. Risk factors of major intraoperative bleeding and postoperative bleeding associated with endoscopic submucosal dissection for gastric neoplasms. Chin. Med. J. 2022, 135, 309–316. [Google Scholar] [CrossRef] [PubMed]
  6. Takeuchi, T.; Ota, K.; Harada, S.; Edogawa, S.; Kojima, Y.; Tokioka, S.; Umegaki, E.; Higuchi, K. The postoperative bleeding rate and its risk factors in patients on antithrombotic therapy who undergo gastric endoscopic submucosal dissection. BMC Gastroenterol. 2013, 13, 136. [Google Scholar] [CrossRef] [Green Version]
  7. Hatta, W.; Tsuji, Y.; Yoshio, T.; Kakushima, N.; Hoteya, S.; Doyama, H.; Nagami, Y.; Hikichi, T.; Kobayashi, M.; Morita, Y.; et al. Prediction model of bleeding after endoscopic submucosal dissection for early gastric cancer: BEST-J score. Gut 2021, 70, 476–484. [Google Scholar] [CrossRef]
  8. Thomas, M.N.; Kufeldt, J.; Kisser, U.; Hornung, H.M.; Hoffmann, J.; Andraschko, M.; Werner, J.; Rittler, P. Effects of malnutrition on complication rates, length of hospital stay, and revenue in elective surgical patients in the G-DRG-system. Nutrition 2016, 32, 249–254. [Google Scholar] [CrossRef]
  9. Gupta, A.; Gupta, E.; Hilsden, R.; Hawel, J.D.; Elnahas, A.I.; Schlachta, C.M.; Alkhamesi, N.A. Preoperative malnutrition in patients with colorectal cancer. Can. J. Surg. 2021, 64, E621–E629. [Google Scholar] [CrossRef]
  10. Aziz, E.F.; Javed, F.; Pratap, B.; Musat, D.; Nader, A.; Pulimi, S.; Alivar, C.L.; Herzog, E.; Kukin, M.L. Malnutrition as assessed by nutritional risk index is associated with worse outcome in patients admitted with acute decompensated heart failure: An ACAP-HF data analysis. Heart Int. 2011, 6, e2. [Google Scholar] [CrossRef]
  11. Ignacio de Ulíbarri, J.; González-Madroño, A.; de Villar, N.G.; González, P.; González, B.; Mancha, A.; Rodríguez, F.; Fernández, G. CONUT: A tool for controlling nutritional status. First validation in a hospital population. Nutr. Hosp. 2005, 20, 38–45. [Google Scholar] [PubMed]
  12. Bouillanne, O.; Morineau, G.; Dupont, C.; Coulombel, I.; Vincent, J.P.; Nicolis, I.; Benazeth, S.; Cynober, L.; Aussel, C. Geriatric Nutritional Risk Index: A new index for evaluating at-risk elderly medical patients. Am. J. Clin. Nutr. 2005, 82, 777–783. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  13. Onodera, T.; Goseki, N.; Kosaki, G. Prognostic nutritional index in gastrointestinal surgery of malnourished cancer patients. Nihon Geka Gakkai Zasshi 1984, 85, 1001–1005. (In Japanese) [Google Scholar]
  14. Takama, T.; Okano, K.; Kondo, A.; Akamoto, S.; Fujiwara, M.; Usuki, H.; Suzuki, Y. Predictors of postoperative complications in elderly and oldest old patients with gastric cancer. Gastric Cancer 2015, 18, 653–661. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  15. Liu, J.; Jiang, S.; Yang, X.; Li, X.; Wang, N. The significant value of preoperative prognostic nutritional index for survival in pancreatic cancers: A meta-analysis. Pancreas 2018, 47, 793–799. [Google Scholar] [CrossRef] [PubMed]
  16. Tokunaga, R.; Sakamoto, Y.; Nakagawa, S.; Izumi, D.; Kosumi, K.; Taki, K.; Higashi, T.; Miyata, T.; Miyamoto, Y.; Yoshida, N.; et al. Comparison of systemic inflammatory and nutritional scores in colorectal cancer patients who underwent potentially curative resection. Int. J. Clin. Oncol. 2017, 22, 740–748. [Google Scholar] [CrossRef]
  17. Choe, Y.H.; Jung, D.H.; Park, J.C.; Kim, H.Y.; Shin, S.K.; Lee, S.K.; Lee, Y.C. Prediction model for bleeding after endoscopic submucosal dissection of gastric neoplasms from a high-volume center. J. Gastroenterol. Hepatol. 2021, 36, 2217–2223. [Google Scholar] [CrossRef]
  18. World Medical Association. World Medical Association Declaration of Helsinki: Ethical principles for medical research involving human subjects. JAMA 2013, 310, 2191–2194. [Google Scholar] [CrossRef] [Green Version]
  19. Ono, H.; Yao, K.; Fujishiro, M.; Oda, I.; Nimura, S.; Yahagi, N.; Iishi, H.; Oka, M.; Ajioka, Y.; Ichinose, M.; et al. Guidelines for endoscopic submucosal dissection and endoscopic mucosal resection for early gastric cancer. Dig. Endosc. 2016, 28, 3–15. [Google Scholar] [CrossRef] [Green Version]
  20. Yamamoto, H.; Kawata, H.; Sunada, K.; Satoh, K.; Kaneko, Y.; Ido, K.; Sugano, K. Success rate of curative endoscopic mucosal resection with circumferential mucosal incision assisted by submucosal injection of sodium hyaluronate. Gastrointest. Endosc. 2002, 56, 507–512. [Google Scholar] [CrossRef]
  21. Yamamoto, H.; Kawata, H.; Sunada, K.; Sasaki, A.; Nakazawa, K.; Miyata, T.; Sekine, Y.; Yano, T.; Satoh, K.; Ido, K.; et al. Successful en-bloc resection of large superficial tumors in the stomach and colon using sodium hyaluronate and small-caliber-tip transparent hood. Endoscopy 2003, 35, 690–694. [Google Scholar] [CrossRef] [PubMed]
  22. Yahagi, N.; Uraoka, T.; Ida, Y.; Hosoe, N.; Nakamura, R.; Kitagawa, Y.; Ogata, H.; Hibi, T. Endoscopic submucosal dissection using the Flex and the Dual knives. Tech. Gastrointest. Endosc. 2011, 13, 74–78. [Google Scholar] [CrossRef]
  23. Ono, H.; Hasuike, N.; Inui, T.; Takizawa, K.; Ikehara, H.; Yamaguchi, Y.; Otake, Y.; Matsubayashi, H. Usefulness of a novel electrosurgical knife, the insulation-tipped diathermic knife-2, for endoscopic submucosal dissection of early gastric cancer. Gastric Cancer 2008, 11, 47–52. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  24. Fujimoto, K.; Fujishiro, M.; Kato, M.; Higuchi, K.; Iwakiri, R.; Sakamoto, C.; Uchiyama, S.; Kashiwagi, A.; Ogawa, H.; Murakami, K.; et al. Guidelines for gastroenterological endoscopy in patients undergoing antithrombotic treatment. Dig. Endosc. 2014, 26, 1–14. [Google Scholar] [CrossRef]
  25. Ono, S.; Fujishiro, M.; Ikeda, Y.; Komuro, I.; Koike, K. Recent clinical management of antithrombotic agents for gastrointestinal endoscopy after revision of guidelines in Japan. Dig. Endosc. 2015, 27, 649–656. [Google Scholar] [CrossRef] [PubMed]
  26. Kato, M.; Uedo, N.; Hokimoto, S.; Ieko, M.; Higuchi, K.; Murakami, K.; Fujimoto, K. Guidelines for gastroenterological endoscopy in patients undergoing antithrombotic treatment: 2017 appendix on anticoagulants including direct oral anticoagulants. Dig. Endosc. 2018, 30, 433–440. [Google Scholar] [CrossRef] [Green Version]
  27. Charlson, M.E.; Pompei, P.; Ales, K.L.; MacKenzie, C.R. A new method of classifying prognostic comorbidity in longitudinal studies: Development and validation. J. Chronic Dis. 1987, 40, 373–383. [Google Scholar] [CrossRef]
  28. Kimura, K.; Takemoto, T. An endoscopic recognition of the atrophic border and its significance in chronic gastritis. Endoscopy 1969, 1, 87–97. [Google Scholar] [CrossRef]
  29. Matsumura, T.; Arai, M.; Maruoka, D.; Okimoto, K.; Minemura, S.; Ishigami, H.; Saito, K.; Nakagawa, T.; Katsuno, T.; Yokosuka, O. Risk factors for early and delayed postoperative bleeding after endoscopic submucosal dissection of gastric neoplasms, including patients with continued use of antithrombotic agents. BMC Gastroenterol. 2014, 14, 172. [Google Scholar] [CrossRef]
  30. Yang, L.; Qi, J.; Chen, W.; Guo, Q.; Xie, R.; Zhao, Z.; Qin, S.; Liu, A.; Den, M.; Fan, C.; et al. Low-dose PPI to prevent bleeding after ESD: A multicenter randomized controlled study. Biomed. Pharmacother. 2021, 136, 111251. [Google Scholar] [CrossRef]
  31. Kanda, Y. Investigation of the freely available easy-to-use software ‘EZR’ for medical statistics. Bone Marrow Transplant. 2013, 48, 452–458. [Google Scholar] [CrossRef] [PubMed]
  32. Park, C.H.; Lee, S.K. Preventing and controlling bleeding in gastric endoscopic submucosal dissection. Clin. Endosc. 2013, 46, 456–462. [Google Scholar] [CrossRef] [PubMed]
  33. Hakoda, A.; Takeuchi, T.; Kojima, Y.; Fujiwara, Y.; Nagami, Y.; Naito, Y.; Fukuda, S.; Koike, T.; Sugimoto, M.; Hamada, K.; et al. Risk factors and prediction of bleeding after gastric endoscopic submucosal dissection in patients on antithrombotic therapy: Newly developed bleeding prediction application software, SAMURAI model. J. Clin. Biochem. Nutr. 2022, 70, 189–196. [Google Scholar] [CrossRef] [PubMed]
  34. Hussain, N.; Alsulaiman, R.; Burtin, P.; Toubouti, Y.; Rahme, E.; Boivin, J.F.; Barkun, A.N. The safety of endoscopic sphincterotomy in patients receiving antiplatelet agents: A case-control study. Aliment. Pharmacol. Ther. 2007, 25, 579–584. [Google Scholar] [CrossRef]
  35. Mannen, K.; Tsunada, S.; Hara, M.; Yamaguchi, K.; Sakata, Y.; Fujise, T.; Noda, T.; Shimoda, R.; Sakata, H.; Ogata, S.; et al. Risk factors for complications of endoscopic submucosal dissection in gastric tumors: Analysis of 478 lesions. J. Gastroenterol. 2010, 45, 30–36. [Google Scholar] [CrossRef]
  36. Kim, J.S.; Lee, K.S.; Kim, Y.I.; Tamai, Y.; Nakahata, R.; Takami, H. A randomized crossover comparative study of aspirin, cilostazol and clopidogrel in normal controls: Analysis with quantitative bleeding time and platelet aggregation test. J. Clin. Neurosci. 2004, 11, 600–602. [Google Scholar] [CrossRef]
  37. Gotoh, F.; Tohgi, H.; Hirai, S.; Terashi, A.; Fukuuchi, Y.; Otomo, E.; Shinohara, Y.; Itoh, E.; Matsuda, T.; Sawada, T.; et al. Cilostazol stroke prevention study: A placebo-controlled double-blind trial for secondary prevention of cerebral infarction. J. Stroke Cerebrovasc. Dis. 2000, 9, 147–157. [Google Scholar] [CrossRef]
  38. Mori, T.; Asano, M.; Ohtake, H.; Bitoh, A.; Sekiguchi, S.; Matsuo, Y.; Aiba, M.; Yamada, M.; Kawada, T.; Takaba, T. Anticoagulant therapy after prosthetic valve replacement -optimal PT-INR in Japanese patients. Ann. Thorac. Cardiovasc. Surg. 2002, 8, 83–87. [Google Scholar]
  39. Choi, J.; Cho, S.J.; Na, S.H.; Lee, A.; Kim, J.L.; Chung, H.; Kim, S.G. Use of direct oral anticoagulants does not significantly increase delayed bleeding after endoscopic submucosal dissection for early gastric neoplasms. Sci. Rep. 2021, 11, 9399. [Google Scholar] [CrossRef]
  40. Chan, E.W.; Lau, W.C.; Mok, M.T.C.; He, Y.; Tong, T.S.M.; Wong, I.C.K. Prevention of dabigatran-related gastrointestinal bleeding with gastroprotective agents: A population-based study. Gastroenterology 2015, 149, 586–595.e3. [Google Scholar] [CrossRef] [Green Version]
  41. Ray, W.A.; Chung, C.P.; Murry, K.T.; Smalley, W.E.; Daugherty, J.R.; Dupont, W.D.; Stein, C.M. Association of oral anticoagulants and proton pump inhibitor cotherapy with hospitalization for upper gastrointestinal tract bleeding. JAMA 2018, 320, 2221–2230. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  42. Borges, P.A.; Waclawiak, I.; Georgii, J.L.; Fraga-Junior, V.D.S.; Barros, J.F.; Lemos, F.S.; Russo-Abrahão, T.; Saraiva, E.M.; Takiya, C.M.; Coutinho-Silva, R.; et al. Adenosine diphosphate improves wound healing in diabetic mice through P2Y12 receptor activation. Front. Immunol. 2021, 12, 651740. [Google Scholar] [CrossRef] [PubMed]
  43. Lee, D.U.; Fan, G.H.; Hastie, D.J.; Addonizio, E.A.; Han, J.; Prakasam, V.N.; Karagozian, R. The clinical impact of malnutrition on the postoperative outcomes of patients undergoing gastrectomy for gastric cancer: Propensity score matched analysis of 2011–2017 hospital database. Clin. Nutr. ESPEN 2021, 46, 484–490. [Google Scholar] [CrossRef] [PubMed]
  44. Toya, Y.; Endo, M.; Akasaka, R.; Morishita, T.; Yanai, S.; Nakamura, S.; Eizuka, M.; Sugimoto, R.; Uesugi, N.; Sugai, T.; et al. Prognostic nutritional index is an independent prognostic factor for older patients aged ≥ 85 years treated by gastric endoscopic submucosal dissection. BMC Gastroenterol. 2021, 21, 328. [Google Scholar] [CrossRef]
  45. Zhang, H.; Tao, Y.; Wang, Z.; Lu, J. Evaluation of nutritional status and prognostic impact assessed by the prognostic nutritional index in children with chronic kidney disease. Medicine 2019, 98, e16713. [Google Scholar] [CrossRef]
  46. Doweiko, J.P.; Nompleggi, D.J. The role of albumin in human physiology and pathophysiology, Part Ⅲ: Albumin and disease states. JPEN J. Parenter. Enter. Nutr. 1991, 15, 476–483. [Google Scholar] [CrossRef]
  47. Schäffer, M.; Barbul, A. Lymphocyte function in wound healing and following injury. Br. J. Surg. 1998, 85, 444–460. [Google Scholar] [CrossRef]
  48. Mueller, S.A.; Mayer, C.; Bojaxhiu, B.; Aeberhard, C.; Schuetz, P.; Stanga, Z.; Giger, R. Effect of preoperative immunonutrition on complications after salvage surgery in head and neck cancer. J. Otolaryngol. Head Neck Surg. 2019, 48, 25. [Google Scholar] [CrossRef]
  49. Thomas, W.G. Duodeno-gastric reflex—A common factor in pathogenesis of gastric and duodenal ulcer. Lancet 1980, 2, 1166–1168. [Google Scholar] [CrossRef]
  50. Nam, H.S.; Choi, C.W.; Kim, S.J.; Kim, H.W.; Kang, D.H.; Park, S.B.; Ryu, D.G. Risk factors for delayed bleeding by onset time after endoscopic submucosal dissection for gastric neoplasm. Sci. Rep. 2019, 9, 2674. [Google Scholar] [CrossRef] [Green Version]
  51. Shiroma, S.; Hatta, W.; Tsuji, Y.; Yoshio, T.; Yabuuchi, Y.; Hoteya, S.; Tsuji, S.; Nagami, Y.; Hikichi, T.; Kobayashi, M.; et al. Timing of bleeding and thromboembolism associated with endoscopic submucosal dissection for gastric cancer in Japan. J. Gastroenterol. Hepatol. 2021, 36, 2769–2777. [Google Scholar] [CrossRef] [PubMed]
Cancers 14 05555 g001 550
Figure 1. Study design flowchart.
Figure 1. Study design flowchart.
Cancers 14 05555 g001
Cancers 14 05555 g002 550
Figure 2. Modified BEST-J score points and percentage of post-ESD bleeding patients at each point in model cohort. Spearman’s rank correlation test was used to determine the correlation coefficient and p-value.
Figure 2. Modified BEST-J score points and percentage of post-ESD bleeding patients at each point in model cohort. Spearman’s rank correlation test was used to determine the correlation coefficient and p-value.
Cancers 14 05555 g002
Cancers 14 05555 g003 550
Figure 3. (A) BEST-J score points and percentage of post-ESD bleeding patients at each point in the validation cohort. Spearman’s rank correlation test was used to determine the correlation coefficient and p-value. (B) Modified BEST-J score points and percentage of post-ESD bleeding patients at each point in the validation cohort. Spearman’s rank correlation test was used to determine the correlation coefficient and p-value. No patients scored 6 or 7.
Figure 3. (A) BEST-J score points and percentage of post-ESD bleeding patients at each point in the validation cohort. Spearman’s rank correlation test was used to determine the correlation coefficient and p-value. (B) Modified BEST-J score points and percentage of post-ESD bleeding patients at each point in the validation cohort. Spearman’s rank correlation test was used to determine the correlation coefficient and p-value. No patients scored 6 or 7.
Cancers 14 05555 g003
Cancers 14 05555 g004 550
Figure 4. Performance comparison between BEST-J score and modified BEST-J score by receiver operating characteristics curve (ROC) analysis. The sensitivity, specificity, positive likelihood ratio, and area under the receiver operating characteristic curve (ROC-AUC) in BEST-J score were 61.5%, 80.1%, 3.09, and 0.75, respectively. Meanwhile, the sensitivity, specificity, positive likelihood ratio, and ROC-AUC in modified BEST-J score were 69.7%, 76.9%, 3.02, and 0.77, respectively. Regarding ROC-AUC, no significant difference was observed between the BEST-J and modified BEST-J scores (p = 0.81).
Figure 4. Performance comparison between BEST-J score and modified BEST-J score by receiver operating characteristics curve (ROC) analysis. The sensitivity, specificity, positive likelihood ratio, and area under the receiver operating characteristic curve (ROC-AUC) in BEST-J score were 61.5%, 80.1%, 3.09, and 0.75, respectively. Meanwhile, the sensitivity, specificity, positive likelihood ratio, and ROC-AUC in modified BEST-J score were 69.7%, 76.9%, 3.02, and 0.77, respectively. Regarding ROC-AUC, no significant difference was observed between the BEST-J and modified BEST-J scores (p = 0.81).
Cancers 14 05555 g004
Table
Table 1. Clinical features and characteristics in model cohort and validation cohort.
Table 1. Clinical features and characteristics in model cohort and validation cohort.
Model CohortValidation Cohortp-Value �
Total299150
Age, mean (SD)73 (9.04)74.1 (9.0)0.197
Males/females, n205/94112/380.226
BMI, mean (SD)23.4 (3.38)23.3 (3.13)0.883
Charson Comorbidity Index, mean (SD)1.27 (1.29)1.44 (1.23)0.186
Undergoing dialysis, n (%)4 (1.34)3 (2.0)0.691
Antithrombotic agent use, n (%)
LDA35 (11.7)12 (8.0)0.255
P2Y12RA15 (5.01)4 (2.67)0.323
PDE3 inhibitor9 (3.01)2 (1.33)0.349
warfarin10 (3.34)11 (7.33)0.094
DOAC8 (2.68)20 (13.3)<0.001
Discontinuation of antithrombotic agent 26 (8.7)26 (17.3)0.0117
Continuation of antithrombotic agent 5 (1.67)15 (10.0)<0.001
Replacement with LDA or heparin 32 (10.7)6 (4.0)0.20
Lesion, n (%)
Tumor size > 30 mm29 (9.7)11 (7.33)0.595
Location at lower 1/3134 (44.5)58 (38.7)0.159
Multiple tumor24 (8.03)11 (7.33)0.854
Undifferentiated tumor3 (1.00)51(0.67)1
Pathologically beyond SM1 invasion28 (9.36)5 (3.33)0.021
ESD procedure, n (%)
Cutting time > 120 minutes35 (11.7)33 (22)0.00529
Failure of en-bloc dissection9 (3.01)4 (2.67)0.758
Presence of mucosal atrophy295 (98.7)138 (92.0)0.00159
Change before and after ESD, mean (SD)
Change in CRP (mg/dL), mean (SD)0.42 (1.05)0.35 (0.62)0.451
Change in WBC (/μL), mean (SD)3290 (2220)3550 (2250)0.289
PNI before ESD, mean (SD)49.6 (5.19)50.3 (5.25)0.206
SD; standard deviation, BMI; Body mass index, LDA; Low dose aspirin, P2Y12RA; P2Y12 receptor antagonist, DOAC; Direct oral anticoagulant, SM; Submucosa, ESD; Endoscopic submucosal dissection, CRP; C-reactive protein, WBC; White blood cell, PNI; Prognostic nutritional index. � p values were determined using Fisher’s exact test or Mann-Whitny U test.
Table
Table 2. Comparison between patients with post-ESD bleeding and without.
Table 2. Comparison between patients with post-ESD bleeding and without.
Post-ESD BleedingControlp-Value �
(n = 25)(n = 274)
Age, mean ± SD73 ± 9.0573 ± 9.170.902
Males/females, n16/9189/850.654
BMI, mean ± SD22.5 ± 2.57 23.5 ± 3.430.28
Charson Comorbidity Index, mean ± SD1.52 ± 1.91.25 ± 1.220.214
Undergoing dialysis, n 310.00197
Antithrombotic agent use, n
LDA5300.191
P2Y12RA69<0.001
PDE3 inhibitor180.549
warfarin190.588
DOAC081
Discontinuation of antithrombotic agent 5210.0527
Continuation of antithrombotic agent 140.411
Replacement with LDA or heparin 5270.165
Lesion, n
Tumor size > 30 mm7210.00439
Location at lower 1/3171170.0199
Multiple tumor3210.436
Undifferentiated tumor031
Pathologically beyond SM1 invasion3250.716
ESD procedure, n
Cutting time > 120 minutes6290.0945
Failure of en-bloc dissection180.549
Presence of mucosal atrophy252701
Change before and after ESD, mean (SD)
Change in CRP (mg/dL), mean (SD)0.661 ± 1.530.393 ± 0.9980.995
Change in WBC (/μL), mean (SD)3826 ± 28703262 ± 21550.495
PNI before ESD, mean ± SD46.2 ± 4.7950 ± 5.12<0.001
PNI ≤ 47.9 ‡, n1892<0.001
SD; standard deviation, BMI; Body mass index, LDA; Low dose aspirin, P2Y12RA; P2Y12 receptor antagonist, DOAC; Direct oral anticoagulant, SM; Submucosa, ESD; Endoscopic submucosal dissection, CRP; C-reactive protein, WBC; White blood cell, PNI; Prognostic nutritional index. � p values were determined using Fisher’s exact test or Mann-Whitny U test. ‡ Cut-off value of PNI were based on receiver operating characteristic analysis.
Table
Table 3. Independent risk factors for post-ESD bleeding.�.
Table 3. Independent risk factors for post-ESD bleeding.�.
PredictorOR (95% CI)VIFp Valueβ Regression CoefficientScore ‡
P2Y12RA use10.5
(2.73–40.3)		1.05<0.0012.352
Tumor size > 30 mm6.79
(2.07–22.2)		1.070.001571.912
Location at lower 1/33.49
(1.24–9.83)		1.060.0181.251
PNI ≤ 47.97.48
(2.39–23.4)		1.07<0.0012.012
OR; Odds ratio, CI; confidence interval, VIF; Variance inflation factor, P2Y12RA; P2Y12 receptor antagonist. � OR, 95% CI and p values were determined using multivariable logistic regression analysis. ‡ Scores were assigned by rounding off the β regression coefficient.
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Share and Cite

MDPI and ACS Style

Okada, T.; Mikamo, T.; Hamamoto, W.; Iwamoto, T.; Okamoto, T.; Maeda, K.; Yanagitani, A.; Tanaka, K.; Isomoto, H.; Yamaguchi, N. Modified BEST-J Score Model Predicts Bleeding after Endoscopic Submucosal Dissection with Fewer Factors. Cancers 2022, 14, 5555. https://doi.org/10.3390/cancers14225555

AMA Style

Okada T, Mikamo T, Hamamoto W, Iwamoto T, Okamoto T, Maeda K, Yanagitani A, Tanaka K, Isomoto H, Yamaguchi N. Modified BEST-J Score Model Predicts Bleeding after Endoscopic Submucosal Dissection with Fewer Factors. Cancers. 2022; 14(22):5555. https://doi.org/10.3390/cancers14225555

Chicago/Turabian Style

Okada, Tomoyuki, Tsuyoshi Mikamo, Wataru Hamamoto, Taku Iwamoto, Toshiaki Okamoto, Kazunori Maeda, Atsushi Yanagitani, Kiwamu Tanaka, Hajime Isomoto, and Naoyuki Yamaguchi. 2022. "Modified BEST-J Score Model Predicts Bleeding after Endoscopic Submucosal Dissection with Fewer Factors" Cancers 14, no. 22: 5555. https://doi.org/10.3390/cancers14225555

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop